ESIDRIX
LOE ApproachingNDAORALTABLET
Approved
Feb 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ESIDRIX is an oral tablet small-molecule drug approved in 1959 by Novartis. The generic name and mechanism of action are not specified in available data, but it is a legacy NDA product. The drug's exact indication profile is not documented here, limiting therapeutic context.
LOE Approaching
Approaching loss of exclusivity signals a contracted team focused on generic transition planning and cost-containment strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ESIDRIX offers minimal career growth opportunity given zero linked jobs and LOE status. This product is suitable for professionals in transition management, generic strategy, or those winding down mature product portfolios rather than building long-term brand careers.
Product ManagerRegional Sales Manager
Worked on ESIDRIX at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.